New long-acting insulin configurations are being developed and launched because the patent on Lantus is set to expire so…
Lantus
Lantus Insulin More Effective in Achieving Long Term Blood Sugar Control in Type 2 Diabetes Patients
New results presented by Sanofi at European Association for the Study of Diabetes (EASD) 48th Annual Meeting showed trea…
Lilly’s Investigational Basal Insulin Shows Better Results than Lantus
Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal in…
Lantus Does Not Increase Cancer Risk, New Studies Show
Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the n…
FDA Approves Byetta for Use with Lantus Insulin in the U.S.
The U.S. Food and Drug Administration (FDA) has approved a new use for Amylin and Eli Lilly's type 2 diabetes drug, Byet…
Novo Nordisk’s New Ultra-Long-Acting Insulin Proves Effective for Treatment of Type 2 Diabetes
Novo Nordisk's ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant …
Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments
Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstr…
Novo Nordisk’s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus
Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently und…
Byetta Improves Beta-Cell Function in Type 2 Diabetics
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from a study comparing the effect of long-term …
Lindsey’s Guide to Surviving College with the Big D, The Schedules and Connections Edition
If you can get a schedule that works with your insulin regimen, you’ve been blessed. So try for that...…
